Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.

Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B, Puig N, Sebastián E, Jiménez C, Mateos MV, Oriol A, Rosiñol L, Palomera L, Teruel AI, González Y, Lahuerta JJ, Bladé J, Gutiérrez NC, Fernández-Redondo E, González M, San Miguel JF, García-Sanz R.

Br J Haematol. 2013 Oct;163(2):223-34. doi: 10.1111/bjh.12519. Epub 2013 Aug 16.


Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.

Meissner T, Seckinger A, Rème T, Hielscher T, Möhler T, Neben K, Goldschmidt H, Klein B, Hose D.

Clin Cancer Res. 2011 Dec 1;17(23):7240-7. doi: 10.1158/1078-0432.CCR-11-1628. Epub 2011 Oct 10.


Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Hose D, Rème T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, Shaughnessy JD Jr, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Möhler T, Rossi JF, Jauch A, Klein B, Goldschmidt H.

Haematologica. 2011 Jan;96(1):87-95. doi: 10.3324/haematol.2010.030296. Epub 2010 Sep 30.


The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

Hose D, Seckinger A, Jauch A, Rème T, Moreaux J, Bertsch U, Neben K, Klein B, Goldschmidt H.

Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:84-9.


International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.

Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B.

Cancer. 2011 Mar 1;117(5):1001-9. doi: 10.1002/cncr.25535. Epub 2010 Oct 13. Erratum in: Cancer. 2011 Jul 1;117(13):3060.


Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.

Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B.

Br J Haematol. 2007 Jun;137(6):530-6. Epub 2007 May 9.


Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.

Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Müller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H.

Haematologica. 2010 Jul;95(7):1150-7. doi: 10.3324/haematol.2009.016436. Epub 2010 Mar 10.


The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.

Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B.

Leukemia. 2015 Aug;29(8):1713-20. doi: 10.1038/leu.2015.65. Epub 2015 Mar 10.


Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.

Nemec P, Zemanova Z, Kuglik P, Michalova K, Tajtlova J, Kaisarova P, Oltova A, Filkova H, Holzerova M, Balcarkova J, Jarosova M, Rabasova J, Hruba M, Spicka I, Gregora E, Adam Z, Scudla V, Maisnar V, Schutzova M, Hajek R; Czech Myeloma Group.

Leuk Lymphoma. 2012 May;53(5):920-7. doi: 10.3109/10428194.2011.634042. Epub 2011 Dec 13.


The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.

Sawyer JR.

Cancer Genet. 2011 Jan;204(1):3-12. doi: 10.1016/j.cancergencyto.2010.11.002. Review.


Low-risk identification in multiple myeloma using a new 14-gene model.

Chen T, Berno T, Zangari M.

Eur J Haematol. 2012 Jul;89(1):28-36. doi: 10.1111/j.1600-0609.2012.01792.x.


Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.

Nair B, Shaughnessy JD Jr, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B.

Blood. 2009 Jun 25;113(26):6572-5. doi: 10.1182/blood-2009-02-207803. Epub 2009 Apr 23.


Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.

Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ.

Blood. 2007 Nov 1;110(9):3291-300. Epub 2007 Jul 3.


[Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].

Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ, Zou DH, Qiu LG.

Zhonghua Xue Ye Xue Za Zhi. 2008 Apr;29(4):217-21. Chinese.


Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.

Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B.

Haematologica. 2012 Apr;97(4):622-30. doi: 10.3324/haematol.2011.046821. Epub 2011 Nov 18.


A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B.

Blood. 2007 Mar 15;109(6):2276-84. Epub 2006 Nov 14.


A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR.

Kaiser MF, Walker BA, Hockley SL, Begum DB, Wardell CP, Gonzalez D, Ross FM, Davies FE, Morgan GJ.

Leukemia. 2013 Aug;27(8):1754-7. doi: 10.1038/leu.2013.12. Epub 2013 Jan 15. No abstract available.


Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.

Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2.


Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

van Laar R, Flinchum R, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD Jr.

BMC Med Genomics. 2014 May 17;7:25. doi: 10.1186/1755-8794-7-25.


International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.

Scudla V, Zemanova M, Minarik J, Bacovsky J, Ordeltova M, Indrak K, Budikova M, Dusek L, Farbiakova V.

Neoplasma. 2006;53(4):277-84.


Supplemental Content

Support Center